Directorship Flashcards

0
Q

How much time does a laboratory have to correct a Phase __ deficiency?

A. I.
B. II.

A

A. By the next internal inspection.

B. 30 days.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Which agency is responsible for assigning levels of complexity to laboratory tests?

A

The FDA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

For proficiency testing, how long must a laboratory deal with same vendor before switching to another?

A

One year.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Waived tests:

A. Definition.
B. Examples.

A

A. Simple, relatively foolproof tests of which incorrect performance would not significantly harm the patient.

B. Urine dipstick, fecal occult blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Waived testing:

A. Requirement.
B. Certificate.

A

A. One must follow the manufacturer’s instructions.

B. Certificate of waiver.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Non-waived tests: Types.

A

Moderate-complexity.

High-complexity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Moderate-complexity test:

A. Example.
B. What can make it a high-complexity test.

A

A. Automated procedure (most).

B. Modification.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

High-complexity test: Example.

A

A test that has a significant manual component, e.g. identification of parasites.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Non-waived tests: Regulatory requirements.

A

Qualified laboratory director and testing personnel.

Written procedures for testing.

Positive and negative controls on each day of testing.

Proficiency testing.

Stipulations concerning record-keeping.

Inspection every other year.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Provider-performed microscopy: Complexity.

A

Moderate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Provider-performed microscopy:

A. When?
B. Method.
C. Indication.

A

A. During the patient’s visit.

B. Bright-field or phase-contrast microscopy.

C. The delay of taking the specimen to the laboratory would compromise the specimen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Provider-performed microscopy: Examples (4).

A

Direct wet mounts for microorganisms.

KOH preparations.

Examinations for pinworms.

Ferning tests.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Levels of review of medical devices by the FDA.

A

Clearance.

Approval.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clearance of medical devices: Required form and its intent.

A

Premarket notification or 510(k): Filed by the manufacturer in order to document that the device is substantially equivalent to some FDA-approved device.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Approval of medical devices: Required form and its intent.

A

Premarket application filed by the manufacturer as a formal validation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Requirements to be met by medical devices that are exempt from review by the FDA (4).

A

Proper labeling, including a statement that of device is not cleared or approved by the FDA.

Listing.

Reporting of device malfunction.

Good manufacturing practices.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

The FDA’s classification of medical devices.

A

Based on the risk associated with use of the device:

Class I, Class II, Class III.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Branch of the FDA that regulates blood products.

A

Center for Biologics Evaluation and Research.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Medicare: Intended beneficiaries (3).

A

Those who are

Over 65 years of age, or

Permanently disabled, or

In end-stage renal disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Medicare: Parts that address reimbursement.

A

Part A: Inpatient care, home health care, and care in hospice or a skilled-nursing facility, apart from physicians’ services.

Part B: Outpatient services and inpatient physicians’ services.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Medicare, Part B: System of reimbursement.

A

Fee-for-service.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Medicare: Usual processors of claims.

A

Part A: Fiscal intermediaries.

Part B: Carriers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

ICD:

A. Basis of coding.
B. Version used in billing.

A

A. Diagnoses.

B. International Coding of Diseases - Clinical Modification (ICD-CM).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Health Care Procedural Coding System:

A. Basis of coding.
B. Levels.

A

A. Rendered services.

B. Level I consists of CPT codes, Level II is used for all other services.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Medicare: Which billing codes must be provided in order to get reimbursed?

A

Both ICD and HCPCS codes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Medicare: Information required for reimbursement of pathology services.

A

Documentation of medical necessity in the form of an ICD code provided by the clinician.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Medicare: What is the DRG?

A

Diagnosis-related group: A type of reimbursement which provides a fixed payment according to the inpatient diagnosis, regardless of the length of stay.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Medicare: How different components of pathology services get reimbursed.

A

Professional component: Coded separately from the laboratory billing schedule.

Technical component: Covered by the DRG payment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Medicare: What happens when a claim for an ___ laboratory test is denied?

A. outpatient
B. inpatient

A

A. The patient may get billed; an advanced beneficiary notice (ABN) must be filed.

B. The patient does not get billed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Medicare: What determines payments for physicians’ services?

A

The Physician Fee Schedule, which is based on the Resource-Based Relative-Value Scale.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Medicare: Examples of “unbundling” of laboratory services.

A

Billing separately for tests in a panel.

Billing separately for the cervix and corpus of a uterus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Medicare: Direct-billing law as it applies to laboratories.

A

Medicare must be billed directly by the laboratory that provides the service.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Medicare: Stark law:

A. Synonym.
B. Intent.

A

A. Physician-self-referral law.

B. To prevent the use of “shell laboratories” that only refer testing to real laboratories but bill Medicare directly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Medicare: Components of the anti-kickback law.

A

A laboratory may not use items of value to induce clinicians to use their services.

When trying to attract non-Medicare patients, the laboratory may not charge less than the cost of the testing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Fixed vs. variable costs: Definitions.

A

Fixed costs are unaffected by the total number of tests performed. However, the fixed cost per test decreases as more tests are performed.

Variable costs are affected by the total number of tests performed. However, the variable cost per test does not change.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Fixed costs: Examples.

A

Purchase of instruments, utilities, rent, wages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Direct vs. indirect costs: Definitions.

A

Direct costs are incurred directly from the performance of tests; indirect costs are not.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Direct vs. indirect costs: Examples.

A

Direct costs: Purchase of instruments, reagents.

Indirect costs: Rent, utilities, custodial services, depreciation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Over which costs does a laboratory director have the greatest control?

A

Over direct costs and variable costs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Unit cost:

A. Definition.
B. Derivation.

A

A. The total cost per test.

B. The sum of the variable costs and fixed costs per test.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Break-even point:

A. Definition.
B. Relevance.

A

A. The number of tests to be performed in order for costs to balance revenue, i.e. where net income equals zero.

B. Can help determine whether to offer a test or send it out.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Break-even point: Formula.

A

N = FC ÷ (R − VC).

N is the number of tests performed.
FC is the fixed cost.
VC is the variable cost (per test).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Allowances and bad debt: Definitions.

A

Allowances: Not getting reimbursed as much as expected.

Bad debt: Not getting reimbursed at all.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Estimation of revenue based on allowances and bad debt.

A

Revenue = total charges − allowances − bad debt.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Budgeting: When does it begin?

A

About 6 months before the beginning of the budgeted year.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Budget: Components (4).

A

Capital budget.

Personnel budget.

Operating budget.

Allocation budget.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Capital budget:

A. Purpose.
B. How to operate when it is restricted.

A

A. The purchase of more expensive items such as analyzers.

B. If an analyzer is leased instead of purchased, the cost of the analyzer can be accounted for in the operating budget instead.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Personnel budget: How typically expressed.

A

As full-time equivalents.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Operating budget:

A. Purpose.
B. Examples of covered items.

A

A. To account for day-to-day operations.

B. Reagents, send-out tests, blood products.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Allocation budget: Purpose.

A

To account for the laboratory’s share of the hospital’s fixed costs, e.g. utilities, administration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Gaussian distribution: Adjective used to describe it.

A

Parametric, i.e. expressible by a mathematical equation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Mean, median, and mode: Definitions.

A

Mean: Arithmetic average of all data points.

Median: Middle value of the range of values.

Mode: Most frequently occurring value.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Mean, median, and mode:

A. In a perfect Gaussian distribution.
B. In a positively skewed distribution.

A

A. Mean = median = mode.

B. Mean > median > mode.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Standard deviation: Relevance to the shape of the Gaussian curve.

A

Narrow curve: Small standard deviation.

Wide curve: Large standard deviation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Standard deviation: Formula.

A

SD = √[Σ(xi − mean)² ÷ (n − 1)]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Standard deviation: Relevance to percentiles in the Gaussian curve.

A

−1 SD to +1 SD: 68.2% of the population.

−2 SD to +2 SD: 95.5% of the population.

−3 SD to +3 SD: 99.7% of the population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Analytical accuracy vs. diagnostic accuracy.

A

Analytic accuracy: Extent to which a test result approximates the “true value”.

Diagnostic accuracy: Ability of a test to distinguish between groups of patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Analytical accuracy:

A. Quantification.
B. How to control it.

A

A. It has no numerical value.

B. Through periodic calibration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Precision:

A. Definition.
B. What influences it.
C. How to control it.

A

A. The reproducibility of a test result.

B. The random variability inherent in a process.

C. Through daily testing of QC reagents.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Precision within a run:

A. Determinant.
B. Expected value.

A

A. Concentration of the analyte, with low concentrations causing lower precision.

B. 1 to 10%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Precision between runs: Determinants (2).

A

Changing environmental conditions.

Changing technologists (operator bias).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Coefficient of variation:

A. Purpose.
B. Formula.

A

A. To express the precision.

B. CV = SD/mean × 100%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Clinical sensitivity: Formula.

A

Sensitivity = TP/(TP + FN).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Clinical specificity: Formula.

A

Specificity = TN / (TN + FP).

64
Q

Analytical sensitivity:

A. Synonym.
B. Definition.

A

A. Limit of detection.

B. The lowest detectable concentration of analyte.

65
Q

Analytical specificity: Definition.

A

Ability of the assay to detect a certain analyte in the presence of many other substances.

66
Q

Positive predictive value:

A. Definition.
B. Formula.

A

A. The percentage of positive results that actually indicate disease.

B. PPV = TP / (TP + FP).

67
Q

Negative predictive value:

A. Definition.
B. Formula.

A

A. The probability of no disease when the test is negative.

B. NPV = TN / (TN + FN).

68
Q

Prevalence:

A. Effect on PPV and NPV.
B. Effect on sensitivity and specificity.

A

A. A low prevalence decreases PPV and increases NPV; the converse is also true.

B. No effect.

69
Q

Relative risk: Definition.

A

The ratio of the risk, in the presence of a risk factor, to the baseline risk.

70
Q

Relative risk: Formula.

A

RR =

(Number with X who develop Y ÷ Number with X) / (Number in population who develop Y ÷ Number in population).

71
Q

Scales:

A. Interval.

B. Ordinal.

C. Nominal.

A

A. The numbers have their usual mathematical values, e.g. 135 mg/dL.

B. The numbers have assigned values, e.g. 1+, 4+.

C. Categories are used, e.g. positive, negative.

72
Q

Graphs used for illustrating diagnostic accuracy (2).

A

Receiver-operating-characteristic curve.

Dot diagram.

73
Q

ROC curve: Axes.

A

Y-axis: Sensitivity.

X-axis: 1 − specificity.

74
Q

ROC curve: How it is used (2).

A

Points along the curve: Estimation of diagnostic accuracy (sensitivity and specificity) at different cutoffs.

Area under the curve (the c statistic): Quantitation of diagnostic accuracy.

75
Q

ROC curve: Slope and area under curve of a ___.

A. test with perfect discrimination.
B. test with no discrimination.

A

A. Infinity; 1.0.

B. 1.0; 0.5.

76
Q

Dot diagram: How constructed.

A

Quantitative results are expressed as dots, each of which is placed in one of two columns: “disease” or “no disease”.

One can then see how well the test distinguishes at various cutoffs (horizontal lines).

77
Q

Reference intervals: Number of values required.

A

The minimum number required for 90% confidence at the limits of the 95th percentile (2.5% of individuals will be below this range, 2.5% above it).

In practice, at least 20 healthy individuals who are representative of the population being tested.

78
Q

How a laboratory can obtain a reference interval for an analyte (2).

A

Establish its own reference interval.

Take a published or manufacturer’s recommended reference interval and verify it for that particular laboratory.

79
Q

Examples of tests for which population-based reference intervals are not useful (2).

A

Serum lipid levels: Range is based on medical decision-points.

MCV: Varies much between individuals but little within an individual.

80
Q

How new methods or instruments are evaluated before implementation (2).

A

FDA-approved test: Verification.

Non-approved: Validation.

81
Q

Method verification: Requirements (3).

A

The laboratory must

Verify that it can reproduce manufacturer’s claims for precision, accuracy, and reportable range.

Verify reference intervals.

Establish parameters for calibration and QC.

82
Q

Method verification: How the laboratory might go about meeting the requirements (2).

A

Correlation study between the new instrument and an existing one or an outside reference laboratory.

Correlation between new instruments of the same model.

83
Q

Method validation: Requirements (2).

A

The laboratory must

Meet all the requirements of method verification.

Assess sensitivity, specificity, and PPV.

84
Q

Parts of a complete validation plan (3).

A

Validation elements.

Number of specimens to suffice for each element.

Predetermined points of passing or failing.

85
Q

Calibration:

A. Definition.
B. When performed.

A

A. Adjusting the instrument to report the known concentration of analyte in a calibrator.

B. At least every 6 months.

86
Q

Calibrators: Examples (4).

A

Samples from patients.

Commercial calibrators.

Samples from proficiency tests.

Controls.

87
Q

Accuracy: How assessed?

A

By comparison with a previously validated method or with a reference method.

88
Q

Bias: Definition.

A

The difference between the measured value and the “true” value.

89
Q

Proportional bias:

A. Appearance on a correlation study.
B. Relevance to values of analyte.

A

A. The y-intercept is the same as that of the reference method, but the slope is different.

B. Bias is clinically less significant at lower values.

90
Q

Types of method validation.

A

Primary: Based on a previously validated assay or a reference method.

Secondary: Validation between instruments.

91
Q

Analytic specificity: How to test it.

A

Perform a “recovery” experiment, in which a known quantity of analyte must be detected in the presence of interfering substances such as bilirubin, lipids, free hemoglobin.

92
Q

Analytical sensitivity: Determination.

A

Measure a blank sample (no analyte) 20 times.

Calculate the mean and the SD.

The value at 2-3 standard deviations above zero is considered the analytical sensitivity.

93
Q

Functional sensitivity:

A. Synonym.
B. Definition.

A

A. Limit of quantitation.

B. The lowest reliably quantified concentration of analyte, reliability being determined by the CV (often 20%).

94
Q

Carryover studies: When performed.

A

When the analyte has a wide range of concentration, e.g. β-hCG.

95
Q

Carryover studies: How performed.

A

Six samples are used, four of low concentration (samples 1, 2, 3, and 6) and two of high concentration (samples 4 and 5).

Carryover = result of sample 6 − (average of results of 1, 2, and 3 ÷ average of results of 4 and 5).

96
Q

Carryover studies: Desirable result.

A

A carryover of <0.015 (1.5%).

97
Q

Analytical measuring range:

A. Synonym.
B. Definition.

A

A. Linear range.

B. The range over which reliable measurements can be obtained.

98
Q

Analytical measurement range: Determination.

A

Measuring serially diluted samples that contain the analyte of interest.

99
Q

Clinical reportable range:

A. Definition.
B. Relationship to the AMR.

A

A. The highest and lowest values that can be reported accurately.

B. CRR and AMR typically have the same lower limit, but the CRR may have a higher upper value, depending on the feasibility of dilution of samples.

100
Q

Specimen stability: Definition.

A

How long a stored specimen continues to produce reliable results.

101
Q

How often must the medical director review procedures (3)?

A

Initially.

With each change.

Annually.

102
Q

Reagents for quality control:

A. Where obtained?
B. How designed?

A

A. From the manufacturer.

B. They are directed to values at or near the cutoffs.

103
Q

Quality control: What is done when a new lot of control reagents is received (4)?

A

It is reconstituted.

It is run at least 20 times on the instrument.

The results are used to calculate mean and SD.

The mean and the SD are used to make a Levey-Jennings chart.

104
Q

Quality control: Commutable reagents.

A

Those that are biologically similar to patients’ samples.

Most QC reagents are non-commutable.

105
Q

Quality control: According to the CLIA, how often must it be performed in the laboratory?

A

Two levels of QC every 24 hours, or more often if recommended by the manufacturer.

106
Q

Quality control:

A. When is a result considered in control?
B. What is done with other results?

A

A. When it falls within 2 SD of the mean.

B. Westgard’s rules are applied in order to determine whether the result is in control.

107
Q

The 1:3s rule:

A. Definition.
B. Purpose.

A

A. One value is found to be 3 SD from the mean.

B. To detect imprecision.

108
Q

The 2:2s rule:

A. Definition.
B. Purpose.

A

A. Two consecutive values are found to be >2 SD from the mean, on the same side of it.

B. To detect imprecision and systematic bias.

109
Q

The R:4s rule:

A. Definition.
B. Purpose.

A

A. Two values are separated by >4 SD.

B. To detect random error.

110
Q

The 4:1s rule:

A. Definition.
B. Purpose.

A

A. Four consecutive values are found at >1 SD from the mean, on the same side of it.

B. To detect systematic bias.

111
Q

The 10:mean rule:

A. Definition.
B. Purpose.

A

A. Ten consecutive values are found to be on the same side of the mean.

B. To detect systematic bias.

112
Q

Causes of error: Systematic (4).

A

Poor calibration.

Defective blanks.

Degraded reagents or instrument components.

113
Q

Causes of error: Random (4).

A

Bubbles.

Under-filled tubes.

Error by technologist.

114
Q

Addressing results that are out of control: First two steps.

A
  1. Check the reagents and the instrument.
  2. Repeat testing on a new aliquot of QC reagent. Significant correction suggests deterioration of the previously used QC reagent.
115
Q

Addressing results that are out of control: Next three steps.

A

Thorough recheck of instrument and reagents and correction of problems.

Retesting of QC reagents.

Retesting of patients’ samples before reporting.

116
Q

Addressing results that are out of control: What to do if all troubleshooting fails.

A

Take the instrument offline and call for formal maintenance.

117
Q

Constant bias:

A. Appearance on a correlation study.
B. Relevance to values of analyte.

A

A. The slope is the same as that of the reference method, but the y-intercept is different.

B. Bias is clinically less significant at higher values.

118
Q

Type of error that corresponds with

A. A widening distribution of results.
B. A shift of drift of results.

A

A. Random error or imprecision.

B. Systematic bias.

119
Q

Proficiency testing:

A. How many times a year?
B. How many samples per survey?
C. Passing score.

A

A. Three.

B. Five.

C. 80%.

120
Q

Proficiency testing: What happens if the laboratory fails a survey (2)?

A

The laboratory must exceed 80% on the next 2 surveys or face possible suspension of certification.

The cause of the failure must be found and corrected.

121
Q

Proficiency testing: Possible causes of failure (2).

A

Problems with reagents: Check reagent logs.

Problems with instrument: Check calibration and maintenance log.

122
Q

Standard deviation index: Formula.

A

SDI = (laboratory’s result − mean for peer group) ÷ SD for peer group.

123
Q

Proficiency testing: Screening rule.

A. Question.
B. Implication.

A

A. Do 2 or more of the 5 results exceed 1 SDI?

B. Proceed to evaluate the data according to the remaining rules.

124
Q

Proficiency testing: Mean rule.

A. Question.
B. Implication.

A

A. Does the average of the 5 SDIs exceed 1.5?

B. Systematic error is significant.

125
Q

Proficiency testing: 3 SDI rule.

A. Question.
B. Implication.

A

A. Is any result beyond 3 SDIs?

B. Random error is significant.

126
Q

Proficiency testing: 4 SDI rule.

A. Question.
B. Implication.

A

A. Are any 2 results >4 SDI apart?

B. Random error is significant.

127
Q

Proficiency testing: What is a “split” sample?

A

A patient’s sample that is divided between two laboratories as an alternative means of proficiency testing.

128
Q

Proficiency testing: How are target ranges assigned for ___ samples?

A. commutable

B. non-commutable

A

A. Based on a reference method.

B. Based on the mean and SD of data from the peer group, using the SD index.

129
Q

Which phase of testing accounts for most of the errors in laboratory medicine?

A

The pre-analytical phase.

130
Q

Pre-analytical errors: Examples (5).

A

Patient’s age.

Selection of test.

Identification of patient.

Collection of specimen.

Integrity of sample.

131
Q

How often does a patient’s test tube contain a sample from a different patient?

A

About 1 time in 2500.

132
Q

What should be done with a sample when a plasma-based test cannot be performed within 1-2 hours?

A

It should be centrifuged within 1 hour and stored at 4-6 degrees.

133
Q

Why must serum or plasma be separated from red cells for many tests?

A

To prevent spurious results due to continued metabolism, e.g. low glucose, high lactate.

134
Q

Red-top tube:

A. Additive.
B. Purpose.

A

A. Silica (plastic tubes) or none (glass tubes).

B. Serum chemistry, serology.

135
Q

Green-top tube:

A. Additive.
B. Purpose.

A

A. Heparin.

B. Plasma chemistry (e.g. CK, troponin).

136
Q

Blue-top tube:

A. Additive.
B. Purpose.

A

A. Citrate.

B. Coagulation tests.

137
Q

Black-top tube:

A. Additive.
B. Purpose.

A

A. Citrate.

B. Erythrocyte-sedimentation rate.

138
Q

Lavender-top tube:

A. Additive.
B. Purpose.

A

A. EDTA.

B. Cell counts.

139
Q

Yellow-top tube:

A. Additive.
B. Purpose.

A

A. Citrate and dextrose.

B. Blood-bank tests, HLA typing.

140
Q

Gray-top tube:

A. Additive.
B. Purpose.

A

A. Sodium fluoride.

B. Glucose, lactate.

141
Q

Order of draw: Plastic tubes (5).

A
  1. Culture.
  2. Blue-top.
  3. Red-top.
  4. Serum-separator tube.
  5. Additive tubes: Green, lavender, gray.
142
Q

Order of draw: Glass tubes (5).

A

Same as for plastic tubes, except that red-top precedes blue-top.

143
Q

Analyte that can seem alarmingly high in healthy adolescents.

A

Alkaline phosphatase.

144
Q

Changes in analytes that come with advanced age (4).

A

Decreased creatinine clearance.

Decreased glucose tolerance.

Increased lipids.

Increased releasing hormones.

145
Q

Analytes that are affected by eating (5).

A

Glucose.

Triglycerides.

Bilirubin.

Gastrin, insulin.

146
Q

Changes in analytes that are brought about by prolonged fasting.

A

Increased: Ketones, bilirubin.

Decreased: Albumin, potassium, magnesium.

147
Q

Analytes that may be increased by ___ exercise.

A. Recent (3).
B. Vigorous.

A

A. CK, LDH, AST.

B. Neutrophil count.

148
Q

Types of analyte that increase when the patient is standing (3).

A

Proteins.

Substances bound to proteins, e.g. calcium.

Formed elements, e.g. red blood cells.

149
Q

Analytes that are affected by fist-clenching or prolonged tourniquet time (2).

A

Potassium, lactate.

150
Q

Analytes that are increased in ___.

A. Serum (4).
B. Plasma.

A

A. Calcium, magnesium, LDH, potassium.

B. Plasma proteins, esp. fibrinogen.

All of these occur secondary to clotting.

151
Q

Analytes whose concentrations may be factitiously changed by paraproteinemia (5).

A

Decreased: Bilirubin, albumin, uric acid, sodium.

Increased: Calcium.

152
Q

How paraproteinemia may lead to hypercalcemia (3).

A

Factitious hypercalcemia due to the turbidity of the paraprotein.

True total hypercalcemia due to increased transport of calcium by the paraprotein (ionized calcium remains normal).

True total and ionized hypercalcemia due to the myeloma itself.

153
Q

Factitious hyperkalemia caused by leukocytosis or thrombocytosis: Serum vs. plasma.

A

Potassium is significantly higher in the serum.

With true hyperkalemia, there should be little or no difference.

154
Q

Chemical analyte that is increased with CML.

A

B₁₂.

155
Q

Post-analytical errors: Examples (4).

A

Errors in

Issuing the report.

Reading (or hearing) the report.

Interpreting the report.

Responding to the report.

156
Q

Estimation of body surface area: Formula.

A

BSA ≈ √(height × weight ÷ 3600).

157
Q

β₂

A

β₂